An investigational individualized neoantigen therapy studied in patients with high-risk melanoma is a collaboration between Moderna and Merck. A previous version of this article referred to it as Moderna's therapy.
Moderna (MRNA) and Merck & Co. (MRK) on Monday released new results from a trial evaluating the companies' mRNA-based investigational individualized neoantigen therapy in combination with Merck's Keytruda in patients with high-risk melanoma. The combined therapy demonstrated a meaningful improvement in distant metastasis-free survival, a key secondary endpoint of the study, the companies said in a release. The results "add to the emerging picture of how individualized neoantigen therapy may advance melanoma treatment and the promise it may hold for other types of cancer," Moderna senior vice president Dr. Kyle Holen said in a statement. The new data are being presented for the first time Monday at the American Society of Clinical Oncology annual meeting in Chicago. Moderna shares are up 0.2% on Monday, while Merck shares are up 0.7%.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
Any recommendation, opinion or advice regarding securities or markets contained in such material does not reflect the views of TD Ameritrade, and TD Ameritrade does not verify any information included in such material.